Stevens-Johnson综合征/中毒性表皮坏死松解症最新进展:诊断标准、发病机制与治疗
本文综述了SJS/TEN的诊断标准、免疫发病机制及治疗进展。SJS/TEN是主要药物诱导的严重黏膜皮肤反应,以大面积皮肤剥脱为特征,缺乏共识诊疗方案。综述提出新的诊断标准以提高特异性和全球适用性,强调药物特异性T细胞反应及HLA多态性作用,讨论免疫抑制剂争议及TNF-α抑制剂等新策略。
要点
- SJS/TEN为药物诱导的罕见严重黏膜皮肤反应,以大面积皮肤剥脱为特征。
- 综述提出新诊断标准以提高特异性和全球适用性。
- 发病机制强调药物特异性T细胞反应及HLA多态性作用。
核心结论
- SJS/TEN诊断与治疗缺乏共识,需更稳健的多学科协作以开发有效诊疗工具。
研究设计与样本
- 综述由美国和英国研究人员完成,聚焦SJS/TEN诊断标准、发病机制与治疗进展。
主要发现
- SJS/TEN为罕见严重黏膜皮肤反应,主要药物诱导,以大面积皮肤剥脱区别于其他全身性皮疹。
- 发病机制涉及药物特异性T细胞反应及人类白细胞抗原多态性在疾病发生中的作用。
- 治疗方面存在免疫抑制剂使用争议,TNF-α抑制剂呈现新兴作用。
- 靶向坏死性凋亡及特定免疫细胞通路的新策略及靶向单克隆抗体和抑制剂正在探索。
关键数值与推荐
- 综述提出新诊断标准以提高特异性和全球适用性。
临床怎么用
- 临床需关注SJS/TEN与其他全身性皮疹的鉴别,重视药物暴露史及遗传易感性。
- 治疗决策需权衡免疫抑制剂争议,关注TNF-α抑制剂等新兴选择。
- 倡导多学科协作以改善SJS/TEN患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a severe spectrum of rare mucocutaneous reactions that are primarily drug-induced and characterized by significant morbidity and mortality. These conditions manifest in extensive skin detachment, distinguishing them from other generalized skin eruptions. The rarity and severity of SJS/TEN underscore the importance of accurate diagnostic criteria and effective treatments, which are currently lacking consensus. This review proposes new diagnostic criteria to improve specificity and global applicability. Recent advances in understanding the immunopathogenesis of SJS/TEN are explored, emphasizing the role of drug-specific T-cell responses and human leucocyte antigen polymorphisms in disease onset. The review also addresses current therapeutic approaches, including controversies surrounding the use of immunosuppressive agents and the emerging role of tumour necrosis factor-α inhibitors. Novel therapeutic strategies targeting specific pathogenic mechanisms, such as necroptosis and specific immune cell pathways, are discussed. Furthermore, the development of new drugs based on these insights, including targeted monoclonal antibodies and inhibitors, are examined. The review concludes by advocating for more robust and coordinated efforts across multidisciplinary medical fields to develop effective treatments and diagnostic tools for SJS/TEN, with the aim of improving patient outcomes and understanding the disease and its mechanisms. Stevens–Johnson syndrome (‘SJS’ for short) and toxic epidermal necrolysis (‘TEN’ for short) are rare but serious skin conditions. They are usually caused by a reaction to medication. They cause large areas of the skin to peel off, making them different to other conditions that affect the skin. It is important to have clear ways to diagnose and treat these different conditions. However, healthcare professionals do not all agree on the best methods to use. This review was done by researchers in the USA and the UK. It suggests new ways to diagnose SJS and TEN to make it easier and more accurate for doctors around the world. We looked at the latest research on what causes these conditions. We focused on how the body’s immune system reacts to certain drugs and genetic factors that might make some people more likely to get SJS or TEN. We looked at current treatments, including drugs that suppress the immune system. We then investigated new treatments that block specific parts of the immune response. We call for better cooperation among different medical specialties to develop more effective treatments and tools to diagnose SJS and TEN. This will help improve the lives of people affected by these severe conditions and increase our understanding of SJS and TEN.
引用
- Hama N, Aoki S, Chen CB, et al. Recent progress in Stevens-Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br J Dermatol. 2024. PMID: 39141587. doi:10.1093/bjd/ljae321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。